Skip to main content

Table 2 Characteristics of candidate tetravalent dengue vaccines in various phases of clinical trials

From: Human antibody response to dengue virus: implications for dengue vaccine design

Vaccine type

Manufacturer

Candidate vaccine

Candidate vaccine description

Clinical trial phase

Protective efficacy of vaccine

Attenuated chimera vaccine

(1) Sanofi-Pasteur

CYD-TVD

Recombinant DENV vaccine with yellow fever 17D vaccine strain as backbone and substitution of preM and E protein genes with each of the four DENV serotype

PIII

56.5–60.8 %

(2) US-CDC/Inviragen/Takeda Pharmaceuticals

DENVax

Recombinant DENV vaccine with DENV-2 as backbone and substitution of preM and E protein genes of DENV-1, DENV-3, and DENV-4

PII

1

(3) NIAID

TetraVax-DV

Attenuated tetravalent formulation with a deletion of 30 nucleotides from 3′ UTR of DENV-1, DENV-3 (or chimeric DENV-3/DENV-4), DENV-4, and a chimeric DENV-2/DENV-4

PII

Attenuated vaccine

Mahidol University/Kaketsuken

Attenuated vaccine strains by serial passages in PDK cells

PII

Inactivated vaccine

WRAIR, GSK

TDENV-PIV

Whole purified inactivated vaccine

PI

Subunit vaccine

Merck (Hawaiian Biotech)

DENV-V180

Truncated DENV E protein

PI

DNA vaccine

U.S. Army Medical Research and Material Command/WRAIR

TVDV

Plasmids encoding the prM/E genes of each DENV serotype

PI

  1. aIndicates no data